SEC Tracker
Get the app

Alpha Teknova TKNO

Alpha Teknova Q2 FY24: revenue $9.6M; diluted EPS −$0.13

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Alpha Teknova reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$9.6MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$5.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.13No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$18.6MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$2.8MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Alpha Teknova files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2835) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Immucell ICCC public float $51M, Jun 30, 2025
  2. Volitionrx VNRX public float $73M, Jun 30, 2025
  3. Insight Molecular Diagnostics IMDX public float $32M, Jun 30, 2025
  4. Biomerica BMRA public float $7M, Nov 28, 2025
  5. Cardio Diagnostics Holdings CDIO public float $6M, Jun 30, 2025